Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • adipose distribution
Prediabetes Remission Without Weight Loss: Rethinking Targets to Prevent Type 2 Diabetes
Posted inDiabetes & Endocrinology news

Prediabetes Remission Without Weight Loss: Rethinking Targets to Prevent Type 2 Diabetes

Posted by MedXY By MedXY 11/12/2025
A post hoc analysis of PLIS and replication in the DPP show that achieving prediabetes remission—normalization of glucose—can prevent type 2 diabetes even without net weight loss, via improved insulin sensitivity, β‑cell function and favorable adipose redistribution.
Read More
  • Targeting the Integrin αV-YAP-CTGF Axis: A New Frontier in Treating Congestive Hepatopathy and Liver Carcinogenesis
  • From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy
  • Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up
  • Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk
  • The Cardiovascular-Kidney-Metabolic (CKM) Syndrome Revolution: Mapping Medication Eligibility and Multi-Systemic Benefits
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in